Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

Omeros Corp (OMER) NPV

Sell:$15.50 Buy:$16.89 Change: $0.22 (1.41%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Sell:$15.50
Buy:$16.89
Change: $0.22 (1.41%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Sell:$15.50
Buy:$16.89
Change: $0.22 (1.41%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The Company’s drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens (IOL) replacement. The Company’s clinical-stage development programs are focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, Huntington’s disease and cognitive impairment, and addictive and compulsive disorders. It also offers a diverse group of preclinical programs and platforms that are used to unlock new G protein-coupled receptor (GPCR) drug targets and to generate antibodies.

Contact details

Address:
201 Elliott Ave W
SEATTLE
98119-4240
United States
Telephone:
+1 (206) 6765000
Website:
www.omeros.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
OMER
ISIN:
US6821431029
Market cap:
$974.93 million
Shares in issue:
62.50 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Gregory Demopulos
    Chairman of the Board, President, Chief Executive Officer
  • Michael Jacobsen
    Vice President, Finance, Chief Accounting Officer and Treasurer
  • George Gaitanaris
    Vice President, Science and Chief Scientific Officer
  • Peter Cancelmo
    Vice President, General Counsel, Secretary
  • Peter Williams
    Vice President, Human Resources
  • Christopher Bral
    Vice President - Nonclinical Development
  • Nadia Dac
    Vice President, Chief Commercial Officer
  • Bruce Meiklejohn
    Vice President - Chemistry, Manufacturing and Controls
  • Catherine Melfi
    Vice President - Regulatory Affairs & Quality Systems, Chief Regulatory Officer
  • Tina Quinton
    Vice President - Patents

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.